Evidence map›Paper›PMID 35836977›Full record

ArticleBioMedicine2022

Comparison between the analytical sensitivity and clinical performance of two cobas SARS-CoV-2 tests based on high-throughput and point-of-care systems.

Tsai-Hsiu Lin, Ngoc-Niem Bui, Yu-Chang Chang, Li-Yun Hsu, Yang-Di Su, Chieh-Min Chang, Wei-An Hong, Uyen Nguyen Phuong Le, Su-Hua Huang, Cheng-Wen Lin

Abstract read
In one paragraph

Article in BioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinical Performance of Rapid Antigen Tests for the Detection of SARS-CoV-2 Infection in the Emergency Department and Community: A Retrospective Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tsai-Hsiu LinDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Ngoc-Niem BuiDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, Taiwan.
Yu-Chang ChangDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Li-Yun HsuDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Yang-Di SuDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Chieh-Min ChangDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Wei-An HongDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Uyen Nguyen Phuong LeDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, Taiwan.
Su-Hua HuangDepartment of Medical Laboratory Science and Biotechnology, Asia University, Taichung 41354, Taiwan.
Cheng-Wen LinDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 40402, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study examined analytical sensitivity, specificity, and the clinical performance in detecting SARS-CoV-2 of the Cobas SARS-CoV-2 Test based on the high-throughput Cobas 6800 system and the Cobas SARS-CoV-2 & Flu A/B Test based on the point-of-care cobas Liat system. Methods: The commercial reagents containing SARS-CoV-2 RNA subgenomes were diluted for assessing the sensitivity of the RT-qPCR assay. 385 nasopharyngeal swab specimens taken from contacts of COVID-19 cases were tested for the SARS-CoV-2 detection with both Cobas SARS-CoV-2 Tests. Results: In analytical sensitivity assays, the Cobas SARS-CoV-2 & Flu A/B Test on the Liat system had a lower limit of detection (12.5-25 copies/mL) than the cobas SARS-CoV-2 Test on the cobas 6800 system (25-50 copies/mL). In clinical performance assays, the cobas SARS-CoV-2 Test demonstrated 89.36% (42 out of 47) PPA (positive percent agreement) and 98.82% (334 out of 338) NPA (negative percent agreement) compared to the results of the Cobas SARS-CoV-2 & Flu A/B test. Among five discordant specimens, four had the positive result of the cobas SARS-CoV-2 test, but the negative result of the cobas SARS-CoV-2 & Flu A/B Test. Moreover, these discordant specimens had the Ct values of greater than 33 for the cobas SARS-CoV-2 Test, implying a very small number of virions in the samples. Remarkably, four specimens with a presumptive positive result of the cobas SARS-CoV-2 test had been confirmed by the Cobas SARS-CoV-2 & Flu A/B Test. Next, the scatter plots of the Ct values showed a highly positive correlation between cobas SARS-CoV-2 & Flu A/B Test and the cobas SARS-CoV-2 Test (R-squared value = 0.954-0.962). Conclusions: Both SARS-CoV2 tests of the cobas 6800 and Liat systems produce reliable high throughput and point-of-care assays respectively for the early virus detection and the personal care decision-making during COVID-19 pandemic.

Indexed as

Analytical sensitivityClinical performanceCobas 6800Cobas liatSARS-CoV-2 test

Identifiers

PMID35836977
PMCPMC9236719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.